


Figure 1: 1st generation of production clones of TNFRII-Fc and TNFRII-Fc-IL1ra chimera: 24-well plate expression in serum-free medium

1/9



Direct CM protein Coomassie blue staining to visualize the protein products

2/9

Figure 2: Affinity purification of chimeric TNFRII-Fc-II-1ra


Non-reduced

Reduced

BEST AVAILABLE COPY


3/9

Figure 3: An example of our troubleshooting capability: reducing a degradation problem for chimeric TNFRII-Fc-IL-1ra by altering the first purification step: HPLC analysis of intact and partially degraded chimeric TNFRII-Fc-IL-1ra with TNFRII-Fc control.




4/9


Figure 4: SEC-HPLC analysis of TNFR1I-FC-IL-1ra after formulation and lyophilization




5/9



6/9




7/9



8/9

Figure 8: Cell-based TNF alpha neutralization test



—◆— TNFR II-Fc
marketed

—■— TNFR II-Fc-IL-1ra
In-house TNFR II-Fc

9/9

Figure 9: Cell-based IL-1 neutralization test

